Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients.
about
Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: retrospective analysis of three medical/pharmacy claims databases.Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial.Controversy: Is Benzalkonium Chloride Necessary in Antiglaucoma Drops?Antiglaucoma drugs: The role of preservative-free formulations.Current and emerging medical therapies in the treatment of glaucoma.Medical treatment of glaucoma: present and future.Ophthalmic preservatives: focus on polyquaternium-1.Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.Are preservatives necessary to improve efficacy of some glaucoma drops?Preservative-Free Prostaglandin Analogs and Prostaglandin/Timolol Fixed Combinations in the Treatment of Glaucoma: Efficacy, Safety and Potential Advantages.The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma.
P2860
Q33932282-8238C35C-84E6-4863-876E-2725FFAF4E4BQ34226897-244CF9F2-F3C2-4CCE-99C3-52CF4BBFDCCFQ36543265-5D9841C8-51A1-404A-8EB6-8ED12FBC79CFQ37060734-E3ED2818-3B26-4B8E-B5AA-1D4CE3F1439AQ37853195-314D8A63-7EE0-4123-A46F-903F51C991B4Q37870933-9733C1EF-E6F3-4224-95CD-F2C41EFFF141Q37929746-DD0948BE-F78D-4419-8960-42EE0C2ACCDEQ38226662-C7A5D7B9-5342-4EEB-90F7-A5785750FB46Q41226964-72F236F1-B201-4F7D-845E-9D2EAB3F2391Q42181227-49FC94FE-1A6D-4D35-8C38-5B5A44B54683Q44839882-2342AEE6-A5BF-416A-9CAD-4F2E5CE6E766Q47381165-A02195FE-AE9A-4A6D-AAD3-855B0D059D67Q55362967-DAEB2640-0FBB-433B-B392-0B21B67717F3
P2860
Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Comparison of a non-preserved ...... ion and glaucomatous patients.
@ast
Comparison of a non-preserved ...... ion and glaucomatous patients.
@en
type
label
Comparison of a non-preserved ...... ion and glaucomatous patients.
@ast
Comparison of a non-preserved ...... ion and glaucomatous patients.
@en
prefLabel
Comparison of a non-preserved ...... ion and glaucomatous patients.
@ast
Comparison of a non-preserved ...... ion and glaucomatous patients.
@en
P2093
P2860
P356
P1476
Comparison of a non-preserved ...... ion and glaucomatous patients.
@en
P2093
Besnainou N
Nemeth-Wasmer G
Pouliquen P
Rouland JF
Vounatsos JP
P2860
P304
P356
10.1136/BJO.2005.080424
P407
P577
2006-05-01T00:00:00Z